EICHORCondition: Metastatic Colorectal Cancer · Sponsor: AUM Biosciences Pte Ltd
Sponsor, CRO or site team? See where this study is running → — listed sites, countries and recruiting context. Everything below is written for patients and caregivers.
The study is a 2-part study of Tinodasertib alone or in combination with Pembrolizumab/Irinotecan in patients with CRC.
This description comes directly from the study's public registry record.
HARISH DAVE, MEDICAL · +1 301 275 4356 · harishd@aumbiosciences.com
JOHN PATAVA, PhD · +61 498 071 249 · johnp@aumbiosciences.com
Always discuss trial participation with your own doctor first.
| Chris O'Brien Lifehouse | Camperdown, New South Wales, Australia | Recruiting |
| Prince of Wales Hospital | Wollongong, New South Wales, Australia | Recruiting |
| Pindara Private Hospital, Gold Coast Cancer Care | Benowa, Queensland, Australia | Recruiting |
| Cabrini Hospital | Malvern, Victoria, Australia | Recruiting |
| Ballarat Oncology and Haematology | Wendouree, Victoria, Australia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05462236